Open access
Open access
Powered by Google Translator Translator

RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).

12 Jan, 2022 | 08:43h | UTC

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma – University of Texas M. D. Anderson Cancer Center

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.